| 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. F Cosentino, PJ Grant, V Aboyans, CJ Bailey, A Ceriello, V Delgado, ... European heart journal, 2019 | 7317* | 2019 |
| 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the … V Regitz-Zagrosek, JW Roos-Hesselink, J Bauersachs, ... European heart journal 39 (34), 3165-3241, 2018 | 4228 | 2018 |
| 2023 ESC Guidelines for the management of acute coronary syndromes RA Byrne, X Rossello, JJ Coughlan, E Barbato, C Berry, A Chieffo, ... European Heart Journal 44 (38), 3720-3826, 2023 | 1712* | 2023 |
| Role of prostacyclin in the cardiovascular response to thromboxane A2 Y Cheng, SC Austin, B Rocca, BH Koller, TM Coffman, T Grosser, ... Science 296 (5567), 539-541, 2002 | 1085 | 2002 |
| 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment … TA McDonagh, M Metra, M Adamo, RS Gardner, A Baumbach, M Böhm, ... European Heart Journal 44 (37), 3627-3639, 2023 | 994 | 2023 |
| 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by … V Delgado, N Ajmone Marsan, S de Waha, N Bonaros, M Brida, H Burri, ... European heart journal 44 (39), 3948-4042, 2023 | 626 | 2023 |
| 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients … N Marx, M Federici, K Schütt, D Müller-Wieland, RA Ajjan, MJ Antunes, ... European heart journal 44 (39), 4043-4140, 2023 | 589 | 2023 |
| Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years GIS Policitemia Annals of Internal Medicine 123, 656-664, 1995 | 586 | 1995 |
| Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets B Rocca, P Secchiero, G Ciabattoni, FO Ranelletti, L Catani, L Guidotti, ... Proceedings of the National Academy of Sciences 99 (11), 7634-7639, 2002 | 447 | 2002 |
| MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single … M Seri, A Pecci, F Di Bari, R Cusano, M Savino, E Panza, A Nigro, P Noris, ... Medicine 82 (3), 203-215, 2003 | 415 | 2003 |
| Cyclooxygenases and prostaglandins: shaping up the immune response B Rocca, GA FitzGerald International immunopharmacology 2 (5), 603-630, 2002 | 340 | 2002 |
| 2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing … GYH Lip, JP Collet, M Haude, R Byrne, EH Chung, L Fauchier, ... Ep Europace 21 (2), 192-193, 2019 | 324 | 2019 |
| Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays Implications for Aspirin “Resistance” F Santilli, B Rocca, R De Cristofaro, S Lattanzio, L Pietrangelo, A Habib, ... Journal of the American College of Cardiology 53 (8), 667-677, 2009 | 315 | 2009 |
| The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low‐dose aspirin in patients with and without diabetes B Rocca, F Santilli, D Pitocco, L Mucci, G Petrucci, E Vitacolonna, ... Journal of Thrombosis and Haemostasis 10 (7), 1220-1230, 2012 | 283 | 2012 |
| Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis F Andreotti, B Rocca, S Husted, RA Ajjan, J ten Berg, M Cattaneo, ... European Heart Journal 36 (46), 3238-3249, 2015 | 261 | 2015 |
| Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo LP Audoly, B Rocca, JE Fabre, BH Koller, D Thomas, AL Loeb, ... Circulation 101 (24), 2833-2840, 2000 | 259 | 2000 |
| Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target S Pascale, G Petrucci, A Dragani, A Habib, F Zaccardi, F Pagliaccia, ... Blood, The Journal of the American Society of Hematology 119 (15), 3595-3603, 2012 | 248 | 2012 |
| Cyclooxygenase-2 expression and inhibition in atherothrombosis F Cipollone, B Rocca, C Patrono Arteriosclerosis, thrombosis, and vascular biology 24 (2), 246-255, 2004 | 246 | 2004 |
| Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease A Pecci, E Panza, N Pujol‐Moix, C Klersy, F Di Bari, V Bozzi, P Gresele, ... Human mutation 29 (3), 409-417, 2008 | 226 | 2008 |
| Antiplatelet agents for the treatment and prevention of coronary atherothrombosis C Patrono, J Morais, C Baigent, JP Collet, D Fitzgerald, S Halvorsen, ... Journal of the American College of Cardiology 70 (14), 1760-1776, 2017 | 216 | 2017 |
Carlo PatronoProfessor of Pharmacology, Università Cattolica del S. Cuore, Rome, ItalyEmail verificata su unicatt.it
